Andrew Metry
Population Health, School of Medicine and Population Health
Research Fellow in Decision Modelling
a.metry@sheffield.ac.uk
+44 114 222 6253
+44 114 222 6253
Regent Court (ScHARR)
Full contact details
Andrew Metry
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91Ö±²¥
S1 4DA
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91Ö±²¥
S1 4DA
- Profile
-
I joined ScHARR (HEDS) as a Research Associate (Health Economics and Decision Modelling) in January 2019 after completing an MSc in the same field (HEDM) at 91Ö±²¥ (ScHARR) in 2018.
Prior to this I was employed as a Pharmacoeconomist in the Egyptian Ministry of Health; I have worked on a variety of technology appraisals back there, and practiced Decision Modelling aiding decision makers towards appropriate national reimbursement schemes for different health technologies.
- Research interests
-
- Cost-Effectiveness modelling and technology appraisals
Current projects
- I mainly work on single technology appraisals associated with the ScHARR-TAG
- Publications
-
Show: Featured publications All publications
Featured publications
This person does not have any publications available.
All publications
Journal articles
- . International Wound Journal, 21(10).
- . Value in Health Regional Issues, 38, 109-117.
- . Health Technology Assessment, 27(14).
- . Value in Health, 25(12), S144-S145.
- . PharmacoEconomics, 39(8), 879-887.
- . PharmacoEconomics.
- . Health Technology Assessment, 25(21), 1-68.
- . PharmacoEconomics.
- . Health Technology Assessment, 25(39), 1-74.
- Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment.
- A cost-effectiveness analysis of remdesivir for the treatment of hospitalised patients with COVID-19 in England and Wales. Value in Health.
Conference proceedings papers
- . Value in Health, Vol. 22 (pp S577-S578)
- COST-MINIMIZATION ANALYSES OF BIOLOGICAL THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS FROM THE EGYPTIAN HEALTHCARE SYSTEM PERSPECTIVE. VALUE IN HEALTH, Vol. 20(9) (pp A535-A536)
- . Value in Health, Vol. 18(7) (pp A646-A646)
- . Value in Health, Vol. 18(7) (pp A437-A437)
- DEVELOPING HOSPITAL BASED HTA FOR EGYPTIAN CANCER PATIENTS. VALUE IN HEALTH, Vol. 18(3) (pp A102-A102)
Preprints
- Professional activities and memberships
-
- Member of International Society for Pharmacoeconomics and Outcomes Research (ISPOR): Abstract reviewer for annual conferences and congresses